2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Clinical Procedures, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Transplantation, Women’s Health, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, CHIP, Genomics, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Patient Safety, Quality Improvement, Quality of Care, Systems-Based Hematology, Diseases, Bone Marrow Failure Syndromes, Aplastic Anemia, Genetic Disorders, Immunology, Autoimmune Disorders, Autoimmune Hemolytic Anemia, GVHD, Infectious Diseases, Viral, Bacterial, Fungal, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, ALL, CLL, LGL, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Research, AML, Translational Research, MDS, MPN, CML, Clinical Research, Epidemiology, Health Outcomes Research, Real-World Evidence, Survivorship, Study Population, Human, Adult, Elderly, Pediatric
PAPER

2506 Clinical and transplant factors associated with gonadal hormone levels after allogeneic hematopoietic cell transplantation: A longitudinal cohort study

Xinhui Zheng, Yiju Lv2, Erlie Jiang, MD3
1 Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
2 Qingdao University Medical College, Qingdao, China
3 Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China

Background

Gonadal dysfunction is a common late complication of allogeneic hematopoietic cell transplantation (allo-HCT) and can affect reproductive health, bone health, and quality of life. The effects of current conditioning regimens and prophylactic mesenchymal stromal cell (MSC) infusion on gonadal hormone levels after HCT are not well established. Rather than classifying hormonal recovery as a binary outcome, we analyzed longitudinal hormone levels as continuous outcomes and examined clinical and transplant factors associated with post-HCT estradiol and testosterone levels.

Methods

We retrospectively analyzed 2,181 allo-HCT recipients treated between 2014 and 2025. The dataset included 32,456 sex hormone measurements collected from day −180 through day +1,095. Patients aged 10 years or younger were excluded. The primary outcome was the time-weighted mean hormone level during the first year after HCT, calculated as the trapezoidal area under the concentration-time curve divided by 365 days: estradiol (E2) in females and testosterone in males. Multivariable linear regression models using log-transformed outcomes tested associations with age, conditioning regimen, graft-versus-host disease (GVHD) severity, cumulative glucocorticoid exposure, HCT-Comorbidity Index, and underlying disease. Exploratory linear mixed-effects models compared post-HCT hormone trajectories by conditioning regimen and prophylactic MSC exposure. The MSC analysis used stabilized inverse probability of treatment weighting (sIPTW).

Results

The cohort included 938 females (median age, 37.8 years; range, 10.1–66.6) and 1,243 males (median age, 36.5 years; range, 10.1–65.0).

Among 679 evaluable females, the median time-weighted E2 level was 6.5 pg/mL. Younger age was independently associated with higher E2 (coefficient per year, −0.010; 95% CI, −0.016 to −0.003; P=0.002). Compared with total body irradiation (TBI)-based conditioning, fludarabine/cyclophosphamide conditioning (Flu/Cy) was associated with higher E2 (coefficient, 1.950; 95% CI, 1.475–2.425; P<0.001), while melphalan/busulfan-based conditioning (Mel/Bu) was associated with lower E2 (coefficient, −0.454; 95% CI, −0.738 to −0.169; P=0.002). Females with lymphoma had lower E2 than those with leukemia (coefficient, −0.881; 95% CI, −1.458 to −0.304; P=0.003). The differences were larger among females aged 20–38 years (n=270): Flu/Cy, coefficient 2.905 (P<0.001); lymphoma, coefficient −1.209 (P=0.014).

Among 1,092 evaluable males, the median time-weighted testosterone level was 9.0 nmol/L. Younger age (coefficient per year, −0.009; 95% CI, −0.014 to −0.004; P<0.001) and lower cumulative glucocorticoid exposure (coefficient per log-unit increase, −0.204; 95% CI, −0.267 to −0.140; P<0.001) were independently associated with higher testosterone. No association was found with underlying disease. In exploratory trajectory analyses, busulfan/cyclophosphamide-based conditioning (Bu/Cy) and Mel/Bu were associated with 16%–20% higher testosterone during days 90–180 than TBI-based conditioning (false discovery rate–adjusted P=0.024). Longer-term recovery proportions were similar across regimens (91%–93%).

Prophylactic MSC infusion was not associated with E2 or testosterone in the full cohort. In an exploratory sIPTW analysis limited to TBI-treated females (n=41), MSC exposure was associated with higher E2 (coefficient, 0.732; P=0.025).

Conclusions

Younger age was associated with higher post-HCT E2 and testosterone levels. Lower cumulative glucocorticoid exposure was associated with higher testosterone in males but not with E2 in females. Associations with E2 differed by conditioning regimen, suggesting that regimen composition may be more relevant than conditioning intensity alone. Lower E2 in females with lymphoma may reflect differences in disease or treatment before HCT. Prophylactic MSC infusion was not associated with hormone levels in the full cohort. The association found in the small subgroup of TBI-treated females requires confirmation. These results may help identify patients at risk for endocrine complications after HCT and guide prospective studies that include gonadotropins, markers of gonadal reserve, treatment exposures, and reproductive outcomes.
Xinhui Zheng: No relevant conflicts of interest to declare.